Amitriptyline Use in Patients on Peritoneal Dialysis

Safety Considerations

When prescribing any medication to peritoneal dialysis patients, careful consideration should be given to drugs that may have adverse effects on residual renal function, as recommended by the American Journal of Kidney Diseases 1
Avoid medications that could potentially harm residual kidney function, as preserving residual renal function is crucial for peritoneal dialysis patients' outcomes, according to the American Journal of Kidney Diseases 1, 2

The KDIGO guidelines note that no existing randomized controlled clinical trials address SSRI use in peritoneal dialysis patients, and evidence for pharmacologic management of anxiety in kidney failure populations is lacking, as stated by the Kidney International 3, 4
For depression management in dialysis patients, non-pharmacological approaches such as aerobic exercise have shown moderate-quality evidence for decreasing depressive symptoms, as reported by the Kidney International 3
If pharmacological treatment is necessary, caution is warranted when prescribing psychotropic medications due to their adverse effect profile in kidney failure patients, according to the Kidney International 3

If residual renal function declines during treatment, consider reassessing the medication regimen and potentially adjusting the dose, as recommended by the American Journal of Kidney Diseases 1, 5
Monitor for QT prolongation and other cardiac effects, which may be particularly concerning in dialysis patients who often have multiple comorbidities, as reported by the Kidney International 3

Patients on peritoneal dialysis have an increased risk of medication-related problems due to polypharmacy, multiple chronic conditions, and altered pharmacokinetics/pharmacodynamics inherent to renal failure, according to the American Journal of Kidney Diseases 6
Medication reconciliation is crucial for patient safety in dialysis, essential to minimize medication-related problems that are a significant cause of morbidity and mortality, as stated by the American Journal of Kidney Diseases 6
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend caution when prescribing psychotropic medications to patients with renal failure due to their adverse effect profile 6